AYTU · Aytu BioPharma Inc. Common Stock
View on chartInsiders & Stakes
| Joshua R. Disbrow Chief Executive Officer | ▲ Buy | Grant | 237,203 Shares held | 7/28/2026 | View profile |
| Mark K. Oki Chief Financial Officer | ▲ Buy | Grant | 190,000 Shares held | 11/18/2022 | View profile |
| Cantrell Gary Director | ▼ Sell | Other | 164,089 Shares held | 12/21/2022 | View profile |
| Jarrett Disbrow Chief Business Officer | ▲ Buy | Grant | 76,568 Shares held | 7/28/2026 | View profile |
| Ryan J. Selhorn Chief Financial Officer | ▲ Buy | Grant | 74,743 Shares held | 7/28/2026 | View profile |
| Greg Pyszczymuka Chief Commercial Officer | ▲ Buy | Grant | 56,102 Shares held | 7/28/2026 | View profile |
| Carl Dockery Director | ▲ Buy | Grant | 31,152 Shares held | 7/28/2026 | View profile |
| Vivian H. Liu Director | ▲ Buy | Grant | 29,825 Shares held | 7/28/2026 | View profile |
| Abhinav Jain Director | ▲ Buy | Grant | 29,500 Shares held | 7/28/2026 | View profile |
| John Donofrio Jr. Director | ▲ Buy | Grant | 23,762 Shares held | 7/28/2026 | View profile |
Transaction History
| Abhinav Jain | ▲ Buy | Grant | 10,000 | $0 | 7/28/2026 |
| Jarrett Disbrow | ▲ Buy | Grant | 15,000 | $0 | 7/28/2026 |
| Ryan J. Selhorn | ▲ Buy | Grant | 25,000 | $0 | 7/28/2026 |
| Vivian H. Liu | ▲ Buy | Grant | 10,000 | $0 | 7/28/2026 |
| Carl Dockery | ▲ Buy | Grant | 10,000 | $0 | 7/28/2026 |
| John Donofrio Jr. | ▲ Buy | Grant | 10,000 | $0 | 7/28/2026 |
| Joshua R. Disbrow | ▲ Buy | Grant | 30,000 | $0 | 7/28/2026 |
| Greg Pyszczymuka | ▲ Buy | Grant | 20,000 | $0 | 7/28/2026 |
| Greg Pyszczymuka | ▲ Buy | Grant | 12,500 | $0 | 10/3/2025 |
| Jarrett Disbrow | ▲ Buy | Grant | 19,606 | $0 | 10/3/2025 |
| Jarrett Disbrow | ▲ Buy | Grant | 12,500 | $0 | 10/3/2025 |
| Ryan J. Selhorn | ▲ Buy | Grant | 16,243 | $0 | 10/3/2025 |
| Ryan J. Selhorn | ▲ Buy | Grant | 17,500 | $0 | 10/3/2025 |
| Joshua R. Disbrow | ▲ Buy | Grant | 31,446 | $0 | 10/3/2025 |
| Joshua R. Disbrow | ▲ Buy | Grant | 22,500 | $0 | 10/3/2025 |
| Vivian H. Liu | ▲ Buy | Grant | 10,000 | $0 | 10/3/2025 |
| Abhinav Jain | ▲ Buy | Grant | 10,000 | $0 | 10/3/2025 |
| Carl Dockery | ▲ Buy | Grant | 10,000 | $0 | 10/3/2025 |
| John Donofrio Jr. | ▲ Buy | Grant | 10,000 | $0 | 10/3/2025 |
| Jarrett Disbrow | ▲ Buy | Open Market | 16,666 | $25K | 6/9/2025 |
| Joshua R. Disbrow | ▲ Buy | Open Market | 66,666 | $100K | 6/9/2025 |
| Greg Pyszczymuka | ▲ Buy | Option Exercise | 209 | — | 3/31/2025 |
| Joshua R. Disbrow | ▲ Buy | Open Market | 15,000 | $20K | 2/28/2025 |
| Ryan J. Selhorn | ▲ Buy | Option Exercise | 105 | — | 2/5/2025 |
| Greg Pyszczymuka | ▲ Buy | Option Exercise | 208 | — | 12/31/2024 |
| Ryan J. Selhorn | ▲ Buy | Grant | 14,000 | $0 | 11/11/2024 |
| Carl Dockery | ▲ Buy | Grant | 1,500 | $0 | 11/6/2024 |
| John Donofrio Jr. | ▲ Buy | Grant | 1,500 | $0 | 11/6/2024 |
| Abhinav Jain | ▲ Buy | Grant | 1,500 | $0 | 11/6/2024 |
| Vivian H. Liu | ▲ Buy | Grant | 1,500 | $0 | 11/6/2024 |
| Greg Pyszczymuka | ▲ Buy | Option Exercise | 209 | — | 9/30/2024 |
| Greg Pyszczymuka | ▲ Buy | Option Exercise | 208 | — | 6/30/2024 |
| Greg Pyszczymuka | ▲ Buy | Option Exercise | 208 | — | 3/31/2024 |
| Greg Pyszczymuka | ▲ Buy | Option Exercise | 209 | — | 12/31/2023 |
| Greg Pyszczymuka | ▲ Buy | Option Exercise | 208 | — | 9/30/2023 |
| Abhinav Jain | ▲ Buy | Grant | 6,500 | $0 | 8/16/2023 |
| Abhinav Jain | ▲ Buy | Grant | 1,500 | $0 | 8/11/2023 |
| Vivian H. Liu | ▲ Buy | Grant | 1,500 | $0 | 8/11/2023 |
| Carl Dockery | ▲ Buy | Grant | 1,500 | $0 | 8/11/2023 |
| John Donofrio Jr. | ▲ Buy | Grant | 1,500 | $0 | 8/11/2023 |
| Greg Pyszczymuka | ▲ Buy | Option Exercise | 208 | — | 6/30/2023 |
| Greg Pyszczymuka | ▲ Buy | Open Market | 12,000 | $22K | 6/16/2023 |
| Joshua R. Disbrow | ▲ Buy | Open Market | 14,000 | $26K | 6/14/2023 |
| Greg Pyszczymuka | ▲ Buy | Option Exercise | 833 | $0 | 4/25/2023 |
| Vivian H. Liu | ▲ Buy | Grant | 6,500 | $0 | 2/8/2023 |
| Carl Dockery | ▼ Sell | Other | 40,000 | $0 | 12/21/2022 |
| Cantrell Gary | ▼ Sell | Other | 40,000 | $0 | 12/21/2022 |
| John Donofrio Jr. | ▼ Sell | Other | 187,804 | $0 | 12/21/2022 |
| Joshua R. Disbrow | ▼ Sell | Other | 80,000 | $0 | 12/20/2022 |
| Joshua R. Disbrow | ▲ Buy | Open Market | 112,371 | $25K | 12/19/2022 |
| Greg Pyszczymuka | ▲ Buy | Open Market | 100,000 | $24K | 12/19/2022 |
| Joshua R. Disbrow | ▲ Buy | Grant | 222,000 | $53K | 11/18/2022 |
| Mark K. Oki | ▲ Buy | Grant | 90,000 | $21K | 11/18/2022 |
| Vivian H. Liu | ▲ Buy | Grant | 6,500 | $0 | 7/1/2022 |
| Mark K. Oki | ▲ Buy | Grant | 100,000 | $0 | 1/17/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Ascendiant Keeps Positive Outlook on Aytu, Raises Target to $15
Ascendiant Capital keeps a bullish view and raised its target to $15. The target sits well above the 52‑week high of $3.06, indicating a potential upside. The stock is currently trading near its support level of $2.17 and has an RSI of 45.6, suggesting neither overbought nor oversold conditions.
Ascendiant Keeps Positive Outlook on Aytu, Raises Target to $15. Ascendiant Capital keeps a bullish view and raised its target to $15. The target sits well above the 52‑week high of $3.06, indicating a potential upside. The stock is currently trading near its support level of $2.17 and has an RSI of 45.6, suggesting neither overbought nor oversold conditions.